Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
Not Applicable
Completed
- Conditions
- Pneumonia, Pneumocystis CariniiHIV Infections
- Registration Number
- NCT00002043
- Lead Sponsor
- Jacobus Pharmaceutical
- Brief Summary
To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3. To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie dapsone's efficacy against Pneumocystis carinii in HIV patients with CD4 <400?
How does dapsone 100 mg compare to 50 mg in preventing PCP in AIDS-Related Complex patients with oral thrush or hairy leukoplakia?
Which biomarkers correlate with dapsone response in HIV-infected individuals with CD4 lymphocyte counts <400/mm3?
What are the long-term adverse event profiles of dapsone prophylaxis in AIDS-Related Complex patients with CD4 <400?
How does dapsone compare to other PCP prophylactic agents like trimethoprim-sulfamethoxazole in HIV patients with CD4 <400?
Trial Locations
- Locations (1)
UCLA CARE Ctr
🇺🇸Los Angeles, California, United States
UCLA CARE Ctr🇺🇸Los Angeles, California, United States